SHANGHAI, China, June 5, 2026
Mabwell announced that China’s National Medical Products Administration (NMPA) has granted Investigational New Drug (IND) clearance for 9MW5211, allowing the company to initiate clinical trials evaluating the novel antibody therapy for inflammatory bowel disease (IBD). The approval marks a significant development milestone for the company’s autoimmune disease pipeline and positions 9MW5211 as the first clinical-stage candidate globally targeting this specific immune-related pathway. The clearance follows earlier authorization from the U.S. Food and Drug Administration (FDA) to conduct clinical studies and further expands the program’s international development strategy.
Novel Antibody Designed to Target Pathogenic Immune Cells
9MW5211 is a highly specific and depleting monoclonal antibody engineered to selectively target pathogenic immune cells involved in autoimmune disease progression. The therapy focuses on a target molecule expressed on activated immune cells that play a central role in chronic inflammation and tissue damage. By selectively recognizing and eliminating these disease-driving cells, 9MW5211 is designed to interrupt immune-mediated inflammatory cascades while minimizing effects on healthy immune populations. According to Mabwell, extensive molecular engineering has optimized the antibody’s selectivity, enabling efficient depletion of target cells while reducing the risk of non-specific binding and off-target effects.
Preclinical Data Demonstrate Therapeutic Potential
Preclinical studies have shown encouraging activity for 9MW5211 across multiple autoimmune disease models. Research conducted in animal models demonstrated significant therapeutic effects, supporting the potential application of the therapy beyond inflammatory bowel disease. Safety evaluations performed in cynomolgus monkeys also indicated a favorable safety profile, providing additional support for clinical development. Mabwell believes the antibody’s mechanism of action may offer the potential for deeper disease remission and extended dosing intervals, which could improve treatment adherence and quality of life for patients managing chronic autoimmune conditions.
Advertisement
Expanding Development Across Autoimmune Diseases
The NMPA clearance for inflammatory bowel disease represents an important step in Mabwell’s broader strategy to develop innovative therapies for immune-mediated diseases. In addition to IBD, the company has submitted clinical trial applications in China for several other indications, including multiple sclerosis (MS), with additional programs under active development. As the prevalence of autoimmune diseases continues to increase globally, Mabwell aims to position 9MW5211 as a potentially first-in-class therapy capable of addressing significant unmet medical needs. The initiation of clinical studies will provide the first opportunity to evaluate the antibody’s safety, tolerability, and therapeutic potential in patients suffering from inflammatory bowel disease.
Source: Mabwell, press release
